Emerging drugs for the management of cancer treatment induced bone loss. - Wikidata - awgldk - TriplyDB

Emerging drugs for the management of cancer treatment induced bone loss.

Emerging drugs for the management of cancer treatment induced bone loss.

http://www.wikidata.org/entity/Q37727235

about

Cisplatin inhibits bone healing during distraction osteogenesis.Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity.Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor.The Italian cross-sectional survey of the management of bone metastasis: ZeTa study.Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures.

P2860

Q33842402-A3FB7867-B181-4D79-B3F5-7B56A06F2F6C Q33918015-F20BDAFB-B9FD-40E5-89ED-A7ECA6BB3FCB Q34559124-DAB290BC-1A0A-4655-B949-8E005644B0BC Q35095538-77BDA611-62B1-4C6C-8D98-144998D9C4B3 Q36491369-ACF439B4-8886-48B3-80A9-5D8E41469360 Q37356084-69AEADC1-C0CB-482E-9CB2-CECD16ED7563 Q53136867-36B59C3F-E19E-436E-930B-B6D4AA7C5529 Q54399590-8D262798-F091-4CA7-BA7D-A32B02787BB9

P2860

Emerging drugs for the management of cancer treatment induced bone loss.

http://www.wikidata.org/entity/Q37727235

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Emerging drugs for the management of cancer treatment induced bone loss.

@en

Emerging drugs for the management of cancer treatment induced bone loss.

@nl

type

label

Emerging drugs for the management of cancer treatment induced bone loss.

@en

Emerging drugs for the management of cancer treatment induced bone loss.

@nl

prefLabel

Emerging drugs for the management of cancer treatment induced bone loss.

@en

Emerging drugs for the management of cancer treatment induced bone loss.

@nl

P1433

Q37727235-AD248677-A85D-4731-A660-823AC1B30AEA

P1476

Q37727235-93F08AC6-E0D8-4B8B-A257-9BB0AD91456C

P2093

Q37727235-03F96E3A-0EA9-4300-A998-DF78C1D1162F

Q37727235-2F0DB985-737E-4AC3-8BE6-03DB0C55FFBA

Q37727235-4AE212AA-AC8F-4BF2-9542-A626312EF7EE

Q37727235-65414A39-32B7-40AC-A648-55A55E7B4EBE

P2860

Q37727235-00A50FAA-6863-4A7C-8523-35CF6977E58E

Q37727235-015FDD93-BBC3-4C28-BE39-92920F282F5D

Q37727235-032D2C75-7EE7-439B-92F3-FBC7A57261F3

Q37727235-0576B1D3-2792-4CBC-B477-93F5C4C15449

Q37727235-082E8E00-B069-48E1-92AD-613A29BA9275

Q37727235-0836DA02-517E-4734-81C6-DE13E5A852D1

Q37727235-08737C9C-5026-450A-A840-B23E06C7CC09

Q37727235-09D036AC-30D3-4DF5-B308-D2C2DC313E3B

Q37727235-0AAE6940-73E8-4390-A786-8396B4201CD7

Q37727235-0B698EA8-7300-4BBE-A2E1-08A299BB4D46

P304

Q37727235-7750003E-7550-4390-8737-5895AD170E74

P31

Q37727235-994E9BBE-2F75-4AFE-AE54-C964E5F30E14

P356

Q37727235-4075AACC-427A-47E5-8164-2A316CF7E245

P407

Q37727235-A9D5E91E-F0FE-4E76-A0E4-AA3C6DC66F4B

P433

Q37727235-7A4D8219-4015-4835-9CE5-5ECA3C3E1DFE

P478

Q37727235-B4D064E5-198F-456D-90FC-842E8645CC81

P577

Q37727235-0484E504-F69B-48B5-A2D2-0C0D3A9BB2A1

P698

Q37727235-EB58C8F1-CC0B-4C55-94E5-4C1B5D3223CB

P356

14728211003631385

P1433

Expert Opinion on Emerging Drugs

P1476

Emerging drugs for the management of cancer treatment induced bone loss.

@en

P2093

Francesco Bertoldo

http://www.w3.org/2001/XMLSchema#string

Serena Pancheri

http://www.w3.org/2001/XMLSchema#string

Sonia Zenari

http://www.w3.org/2001/XMLSchema#string

Stefania Boldini

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Vitamin D deficiency

A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

Bone morphogenetic proteins

Ihh signaling is directly required for the osteoblast lineage in the endochondral skeleton

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action.

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

P304

323-342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728211003631385

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20377485

http://www.w3.org/2001/XMLSchema#string